Bristol Myers says it needs another year to hit target for new drugs

Drugmaker Bristol Myers Squibb (BMY.N) on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.